Moderna, Inc. (MRNA) shares rose 4.37% to $57.55 after the biotechnology company announced it has initiated a Phase 1 clinical trial in Canada for its experimental Bundibugyo Ebola vaccine candidate, mRNA-1469. Health Canada authorized the study, and the first participants have already been dosed.

The milestone marks significant progress toward a protective vaccine against a viral strain for which no approved prevention measures currently exist.

Canadian Phase 1 Study Underway

Moderna is conducting the clinical investigation across three research centers in Canada. The study will evaluate safety, tolerability, and immunogenicity in approximately 80 healthy adult volunteers.

The mRNA-1469 candidate is built on the same messenger RNA technology platform that underpinned Moderna's COVID-19 vaccine. The company drew on prior filovirus research and studies of related Ebola virus species, which enabled an accelerated transition from preclinical laboratory work to human clinical evaluation. The modular nature of mRNA technology — where the delivery system remains constant while the genetic code can be swapped for a new pathogen — has been central to this speed advantage.

This trial represents the first human assessment of Moderna's approach to preventing Bundibugyo ebolavirus infection. No authorized vaccine currently exists for this particular strain. Available Ebola immunizations predominantly target Zaire ebolavirus, including Ervebo by Merck and the two-dose regimen by Johnson & Johnson — the only WHO-prequalified Ebola vaccines. Neither is designed to protect against the Bundibugyo species driving the current epidemic.

CEPI Funding Supports Development

The Coalition for Epidemic Preparedness Innovations (CEPI) has committed up to $50 million to advance the vaccine program through preclinical research, Phase 1 clinical evaluation, and manufacturing of clinical supply doses during early-stage development. This funding model aims to compress the interval between initial results and subsequent expanded trials.

Moderna plans to use data from the Phase 1 study to inform the design of potential Phase 2 and Phase 3 trials. Parallel manufacturing efforts would allow rapid scale-up if preliminary results prove encouraging. However, advancement to later development stages remains contingent on demonstrating adequate safety profiles and robust immune responses.

The collaborative agreement includes provisions for vaccine access in resource-limited settings. Moderna has committed to reserving at least 500,000 doses for distribution in low- and middle-income countries, to be made available through tiered pricing structures following regulatory approval.

DRC Outbreak Underscores Urgency

The ongoing epidemic in the Democratic Republic of the Congo is driven by Bundibugyo ebolavirus transmission. Public health officials have documented more than 3,000 laboratory-confirmed infections and over 1,400 fatalities, placing the outbreak among the most severe filovirus public health crises on record.

The World Health Organization has designated the situation a Public Health Emergency of International Concern. The Africa Centres for Disease Control and Prevention has similarly declared a Public Health Emergency of Continental Security. Both declarations reflect the outbreak's scale, transmission velocity, and expanding geographic reach.

The Canadian trial offers global health authorities a potential additional preventive tool against the circulating outbreak strain. Moderna must still complete the full clinical testing pathway before regulatory bodies can evaluate the candidate for licensure. Initial safety and immunogenicity readouts from the Phase 1 cohort will be key indicators of whether the program advances to expanded trials. The program also expands Moderna's infectious disease portfolio — which includes candidates targeting respiratory syncytial virus, influenza, and cytomegalovirus — and strengthens its broader mRNA vaccine research capabilities.